Key Highlights

  • Adaptive Biotechnologies reported second-quarter 2026 Revenue of $71.6 million, up 22%, driven by its MRD diagnostics business.
  • MRD (clonoSEQ) revenue rose 33% to $66.2 million on test Volume of 36,111, up 43%, and the segment's adjusted EBITDA improved markedly.
  • It raised full-year MRD revenue guidance to $268-$278 million, held $371.7 million in cash, and plans to separate its MRD and Immune Medicine businesses.
  • The planned separation would let investors value a fast-growing, increasingly profitable diagnostics Business independently of the earlier-stage therapeutics arm.

Adaptive Biotechnologies (NASDAQ:ADPT) runs clonoSEQ, a test that detects tiny amounts of residual cancer in blood cancers, a diagnostic capability known as minimal or measurable residual disease testing. Fast-growing test volumes lifted revenue and profitability again this quarter, and the company plans to separate its MRD diagnostics business from its earlier-stage Immune Medicine therapeutics arm, a structural move that reflects just how differently the two businesses are now performing.

MRD stands for minimal, or measurable, residual disease, the small amounts of cancer that can remain in a patient's body after treatment and that conventional tests often cannot detect. Adaptive's clonoSEQ test uses the company's underlying immune-sequencing technology to find those residual traces with far greater sensitivity, helping oncologists monitor whether a blood-cancer patient's treatment is working and whether the disease is likely to return.

The MRD Business Drives Growth

For the second quarter of 2026, Adaptive Biotechnologies reported total revenue of $71.6 million, up 22% year on year, driven substantially by its MRD diagnostics business. MRD revenue specifically, generated through the clonoSEQ test, rose 33% to $66.2 million, on test volume of 36,111, up 43% year on year, a clear signal that adoption of the test is accelerating rather than merely growing incrementally.

The segment's adjusted EBITDA improved markedly alongside that volume growth, evidence that the MRD business is achieving meaningful Operating Leverage as it scales, additional test volume converting to profit at a much higher rate than the underlying cost base grows. The company raised full-year MRD revenue guidance to a range of $268 million to $278 million, and it held $371.7 million in cash at quarter-end, giving it a substantial financial cushion.

Why a Planned Separation Makes Sense

Adaptive Biotechnologies has historically operated two quite different businesses under one roof: the MRD diagnostics business built around clonoSEQ, which is commercial, growing rapidly and increasingly profitable, and an Immune Medicine therapeutics arm focused on earlier-stage drug development, which by its nature is a longer-horizon, capital-intensive, pre-revenue endeavor.

Combining a fast-growing, increasingly profitable diagnostics business with an earlier-stage therapeutics program under a single stock can make it difficult for investors to value either piece appropriately; the market may apply a discount to the profitable diagnostics business because of the drug-development risk attached to it, or undervalue the therapeutics pipeline because it is overshadowed by the diagnostics story. Separating the two businesses would let each be evaluated, and potentially valued, on its own merits.

The Opportunity

The MRD testing market itself represents a substantial and still-expanding opportunity: as clonoSEQ becomes more established as a standard tool for monitoring blood-cancer patients, test volumes and revenue can continue growing well ahead of the underlying cost base, which is exactly what the quarter's 43% volume growth against 33% revenue growth and improving adjusted EBITDA suggest is already happening.

If the planned separation proceeds as outlined, the MRD business could trade as a focused, high-growth diagnostics company, potentially attracting a different, more diagnostics-oriented set of investors than the combined entity does today, while the Immune Medicine business would be free to pursue its therapeutic pipeline without the operational and reporting complexity of the diagnostics business layered on top.

Risks

The MRD business, while growing rapidly, depends on continued adoption by oncologists and continued favorable reimbursement from insurers; any pullback in either would slow the growth trajectory that has driven the recent results. Competition in cancer diagnostics is active, and rival technologies or tests could challenge clonoSEQ's position over time.

The planned separation itself carries execution risk and cost, and there is no guarantee it proceeds exactly as currently outlined or on the expected timeline. The Immune Medicine therapeutics business, once separated, would face the ordinary risks of early-stage drug development, uncertain trial outcomes, regulatory hurdles and the need for its own independent financing, without the cash generation of the MRD business to lean on.

Two Businesses Diverging Fast Enough to Justify Splitting Them

The things to watch are continued clonoSEQ test-volume growth and whether the 43% pace can be sustained, progress and details on the planned separation of the MRD and Immune Medicine businesses, adjusted EBITDA trends in the MRD segment as a measure of operating leverage, and progress against the raised full-year MRD revenue guidance of $268 million to $278 million.

Adaptive Biotechnologies' MRD testing business has become the company's clear growth engine, expanding rapidly and improving profitability at the same time. The planned separation from the earlier-stage Immune Medicine arm reflects just how far the two businesses have diverged, and how differently they now need to be run, funded and valued.